Molecular features of breast cancer predictive of lymph node metastases;Marcadores moleculares em câncer de mama preditivos de metástases axilares

Revista da Associacao Medica Brasileira

Volumn 54, Issue 3, 2008, Pages 203-207

  Marinho, Vanessa Fortes Zschaber ^a   Metze, Konradin ^a   Sanches, Fernanda Squárcio Fernandes ^a   Rocha, Gislene Fátima Silva ^a   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Axillary metastases; Breast cancer; Hematoxylin and Eosin; Immunohistochemistry; Predictive factors

Indexed keywords

CD31 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLA; BLOOD VESSEL; BREAST TUMOR; CANCER INVASION; CHEMISTRY; EPIDEMIOLOGY; FEMALE; HUMAN; LYMPH NODE; LYMPH VESSEL; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; AXILLA; BLOOD VESSELS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 47249154449     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302008000300011     Document Type: Article

References (30)

1. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17:1497-503.
2. Ponzone R, Maggiorotto F, Mariani L, Jacomuzzi ME, Magistris A, Mininanni P, et al. Comparison of two models for prediction of nonsentinel node metastases in breast cancer. Am J Surg. 2007;193:686-92.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
4. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, et al. Age remains the first prognostic factor for locoregional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol. 2007;82:272-80.
5. Finek J, Holubec L Jr, Topolcan O, Elgrova L, Skalova A, Pecen L. The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res. 2007;27:1893-6.
6. Brenin DR, Manasseh D, El-Tamer M, Troxel A, Schnabel F, Ditkoff BA, et al. Factors correlating with lymph node metastases in patients with T1 breast cancer. Ann Surg Oncol. 2001;8:432-7.
7. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat. 1998;51:195-208.
8. Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G. Invasive micropapillary carcinoma of the breast. Clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 2004;121:857-66.
9. Kim MJ, Gong G, Joo HJ, Ahn SH, Ro JY. Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary component. Arch Pathol Lab Med. 2005;129:1277-82.
10. Tawfik O, Kimler BF, Davis M, Stasik C, Lai S, Mayo MS, et al. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. Virchows Arch. 2007;450:627-36.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:1069-74.
12. Marinho VF, Zagury MS, Caldeira LG, Gobbi H. Micrometástases de carcinoma da mama em linfonodos axilares: detecção imunoistoquímica versus hematoxilina e eosina. J Bras Patol Med Lab. 2004;40:127-32.
13. Marinho VF, Zagury MS, Caldeira LG, Gobbi H. Relationship between histologic features of primary breast carcinomas and axillary lymph node micrometastases: detection and prognostic significance. Appl Immunohistochem Mol Morphol. 2006;14:426-31.
14. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. Breast. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al, editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p.223-40.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
16. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-78.
17. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol.2007;18:1632-40.
18. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer. 2006;95:1611-25.
19. Yamauchi C, Hasebe T, Iwasaki M, Imoto S, Wada N, Fukayama M, et al. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol. 2007;38:247-59.
20. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-68.
21. Harvey JM, Clark GM, Osborne CK, Allews DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-81.
22. Dako Herceptest™: A manual for interpretation. Carpinteria: Dako Corp.; 1999.
23. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-Phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol. 1995;104:42-9.
24. Gupta A, Deshpande CG, Badve S. Role of E-Cadherins in development of lymphatic tumor emboli. Cancer. 2003;97:2341-7.
25. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-83.
26. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;191:1-6.
27. Viale G, Zurrida S, Maiorano E. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103:492-500.
28. Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ. Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol. 2007;31:129-40.
29. Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol. 2007;20:183-91.
30. Yonemura Y, Endou Y, Tabachi K, Kawamura T, Yun HY, Kameya T, et al. Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody, D2-40. Hum Pathol. 2006;37:1193-9.